Advertisement

A Universal Cancer Vaccine?

A vaccine that targets 90 percent of all cancers shows promise in early clinical trials.

By | April 10, 2012

image: A Universal Cancer Vaccine? Dreamstime.com, Suto Norbert

DREAMSTIME.COM, SUTO NORBERT

A vaccine that targets the vast majority of cancers has produced encouraging preliminary results in phase I/II clinical trials. According to an announcement made on April 2 by the vaccine’s maker, Vaxil Biotherapeutics, the ImMucin vaccine consists of a 21 amino acid-long peptide that represents a key signaling region of Mucin 1, cell surface associated (or MUC1)—a glycoprotein expressed by 90 percent of solid and non-solid tumors.

In trials carried out at Hadassah Medical Centre in Jerusalem, the vaccine generated a robust immune response in patients with multiple myeloma after only 2 to 4 doses of the vaccine, The Telegraph reported. The patients were administered a maximum of 12 doses.

"In some of the patients, preliminary signs of clinical efficacy were observed," according to a statement from Vaxil Biotheraputics, which will formally publish the results of the trial in the near future.

Advertisement
The Scientist
The Scientist

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Advertisement
Life Technologies